‘Innovation Passport’ Necessary For UK Project Orbis Reviews

MHRA Specifies Prerequisites For International Oncology Drug Review Initiative

 
• By Vibha Sharma

Promising cancer medicines will need to be included in the UK’s new licensing pathway for innovative drugs before the UK medicines regulator will agree to their review under the Project Orbis initiative.

Digital illustration of Cancer cell in colour background
Project Orbis Allows Concurrent Review Of Cancer Drugs By International Partners • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards